Overwhelm Cancer. Defeat Cancer. Transforming Cancer Treatment. Overcoming Drug Resistance.

AtlasMedx, Inc is a privately held, clinical stage biopharmaceutical company advancing highly targeted therapeutics that modulate anti-tumor pathways.

AtlasMedx is advancing AMXI-5001, a first-in class orally bioavailable, small-molecule dual PARP and microtubule polymerization inhibitor.

AtlasMedx aims to dramatically improve the therapeutic outcome and quality of life for cancer patients by developing and commercializing more effective and tolerable therapies to treat advanced and resistant cancers. The company is focused on developing innovative cancer therapies that target well-validated cellular pathways vital to carcinogenesis and drug resistance.

A privately held biopharmaceutical company focused on
developing medically innovative and multifunctional cancer
therapies targeting well-validated compensatory cellular pathways
important to carcinogenesis and drug resistance.